My Application Form Status

Check the status of your application form with Angel Broking.
Arq - The Hyper Intelligent Investment Engine By Angel Broking

Company Research Reports

Company Reports

Result Updates | Jun 15th 2017

UPL Ltd

CMP : 849Target Price : 849

United Phosphorus Ltd. (UPL) posted robust numbers for 4QFY2017. In sales, the company posted gross revenues of `5,341cr v/s `4,434cr in 4QFY2016, growth of 20.5% yoy. The growth was driven by volumes (16% yoy), while growth in pricing was around 2%, which coupled with exchange gains added 2% to the top-line rise. On EBITDA front, the com..

View As PDF

Result Updates | Jun 13th 2017

Cipla Ltd

CMP : 550Target Price : 461

For 4QFY2017, Cipla posted poor set of numbers primarily related to extra-ordinary items. For the quarter, the sales came in at `3487cr v/s. `3,253cr in 4QFY2016, registering a yoy growth of 7.2%, aided by robust growth in export markets. On the OPM front, the EBDITA margins came in at 11.8% (v/s. 16.8% expected) v/s 5.0% in 4QFY2016. Thu..

View As PDF

Sort By

Result Updates | Jun 12th 2017

Indoco Remedies Ltd

CMP : 193
Target Price : 150

Indoco Remedies posted lower than expected numbers for 4QFY2017. In sales, the company posted revenues of `266cr (`311cr expected) v/s. `255cr in 4QFY2016, growth of 4.2% yoy. The formulation business posted sales of `251.6cr, up 3.3% yoy, while API at `12.0cr was down 4.7% yoy. The domestic formulation at `130.1cr recorded a yoy de-growt..

Result Updates | Jun 12th 2017

Sun Pharmaceuticals Industries Ltd

CMP : 525
Target Price : 712

For 4QFY2017, Sun Pharma posted tepid numbers. For the quarter, the sales came in at `6,825cr v/s. `7,600cr expected, registering a yoy dip of 7.9%. India sales at `1,916cr, were up by 10% as compared to 4QFY2016, US finished dosage sales at US$381mn down by 34% vis-à-vis 4QFY2016. On the OPM front, the gross margins came in at 67.8% v/s...

Result Updates | Jun 12th 2017

Lupin Ltd

CMP : 1,161
Target Price : 1,526

For 4QFY2017, Lupin posted results which were much below expectations mainly on OPM and the net profit front. The revenues came in at `4,162cr v/s. `4,338cr, a yoy growth of 1.3%. On the OPM front, the EBDITA margins came in at 16.6% (v/s. 25.7% expected) v/s. 31.2% in 4QFY2016. Thus, the Adj. PAT during the quarter came in at `380.3cr v/..

Result Updates | Jun 05th 2017

Cadila Healthcare Ltd

CMP : 495
Target Price : 495

For 4QFY2017, Cadila Healthcare posted lower than expected results. The sales came in at `2,418cr (v/s. `2,800cr expected) v/s. `2,270cr in 4QFY2016, a yoy growth of 6.5%. On the operating front, the EBITDA margin came in at 16.7% v/s. 21.4% (v/s. 15.7% expected) in 4QFY2016. The GPM’s came in at 61.6% (v/s. 65.7% in 4QFY2016), which resu..

Result Updates | Jun 05th 2017

Natco Pharma Ltd

CMP : 968
Target Price : 1,060

The bumper earnings in 4QFY17 were mostly expected and there was no surprise element. We however believe that company is almost launch ready for gCopaxone in June-2017. We gain significant confidence that Mylan/Natco are most likely to launch the drug soon which is the most important trigger for the Natco at the moment. Company has respon..

Result Updates | Jun 02nd 2017

Aurobindo Pharma Ltd

CMP : 580
Target Price : 823

For 4QFY2017, Aurobindo Pharma (APL) posted numbers which were lower than expectations on sales, OPM & net profit fronts. On sales front, the company posted sales of `3,582cr (v/s. `4,460cr expected) v/s. `3,674cr in 4QFY2016, posting a yoy de-growth of 2.5%. On the operating front, the EBITDA margin came in at 18.5% (v/s. 23.4% expec..

Result Updates | May 31st 2017

Alkem Laboratories Ltd

CMP : 1,868
Target Price : 2,161

Alkem reported yoy revenue grew of 9% in 4QFY17. Domestic revenue grew by 7% yoy to Rs856cr while exports grew by 14.5% to Rs385cr. US revenue grew by 19.4% yoy to Rs291cr. Other exports were flat at Rs95cr. Domestic business contributed 69% of the total revenue during the quarter. Exports mix remains unchanged (vs. 3QFY17), with US contr..

Result Updates | May 31st 2017

Tech Mahindra Ltd

CMP : 388
Target Price : 533

Tech Mahindra posted muted set of numbers for 4QFY2017. For the quarter, sales came in at US$1,131mn v/s 1,129mn expected, registering a qoq growth of 1.3%. In Rupee terms, the sales came in at `7,495cr v/s `7,533cr expected, a qoq de-growth of 0.8%. In Constant Currency (CC) terms, the company posted a 0.9% qoq growth during the quarter...

Result Updates | May 23rd 2017

GlaxoSmithkline Consumer Healthcare Ltd

CMP : 2,428
Target Price : 2,428

GlaxoSmithKline Pharmaceuticals (GSK) posted better than expected results on sales and OPM fronts for 4QFY2017. The revenues came in at `763cr v/s `690cr expected, registering a yoy growth of 10.9%. On the OPM front, the EBDITA margins came in at 15.2% (v/s 11.3% expected) as compared to 16.1% in 4QFY2016. The Adj. PAT for the quarter cam..

Result Updates | May 15th 2017

HCL Technologies Ltd

CMP : 847
Target Price : 1,014

The company posted 4QFY2017 results better than expected. In US$ terms, the revenues came in at US$1,817mn (v/s US$1,810mn expected) v/s US$1,745mn in 3QFY2017, a qoq growth of 4.1%. On Constant Currency (CC) basis, company posted a 3.8% qoq growth. On the operating front, EBIT came in at 20.0% (v/s 20.1% expected) v/s 20.4% in 3QFY2017, ..

Company Research Reports

The Angel Advantage
  • Present in the industry since 1987

  • Technology enabled DEMAT & Trading Account

  • Technical and fundamental research guidance